About

Dr. Andrew R. Berman is a Professor of Medicine at Rutgers New Jersey Medical School, serving as the Division Director of Pulmonary, Critical Care, Allergy, and Rheumatology. He trained in Pulmonary and Critical Care Medicine at The Johns Hopkins Hospital and subsequently joined the faculty at Montefiore Medical Center, Albert Einstein College of Medicine, where he also served as the fellowship training program director. In 2011, he was recruited to NJMS to be the Division Director of Pulmonary/Critical Care Medicine and established the first combined division of Pulmonary and Critical Care Medicine/Allergy and Immunologic Diseases at NJMS. Dr. Berman's professional activities include serving as Past-President of the New Jersey Thoracic Society and participating in committees for the American College of Chest Physicians, the American Thoracic Society, and the American Lung Association. He directs the Pulmonary Course for medical students at NJMS and has received awards for his teaching from NJMS and the New Jersey Health Foundation. His international work includes being a visiting professor at the University KwaZulu-Natal in South Africa and collaborating with Project Medishare in Haiti. His research interests focus on healthcare disparities and clinical outcomes research. Clinically, Dr. Berman sees patients with a wide variety of lung diseases, with particular interest in sarcoidosis, COPD, and advanced lung diseases.

Research topics

• Medicine
• Biology
• Intensive care medicine
• Internal medicine
• Immunology
• Virology

Selected publications

• Neuropathologic Findings in Mowat-Wilson Syndrome at Autopsy, Including a Suprasellar Spindle Cell Lipoma

  Pediatric and Developmental Pathology · 2025-04-24

  article

  Mowat-Wilson Syndrome is an autosomal dominant disorder caused by de novo heterozygous mutations of ZEB2 on 2q22. It is characterized by developmental delay, Hirschsprung’s disease, seizures, and a wide variety of malformations affecting the neurologic, cardiac, and genitourinary systems. Reports describing the findings of Mowat-Wilson Syndrome at autopsy are sparse. Case reports of suprasellar spindle cell lipomas are even rarer, a circumstance that contributes to uncertainty regarding their etiology as true neoplasms rather than congenital malformations. Here we report the gross, histopathologic, and molecular findings of a 4-year-old female with Mowat-Wilson Syndrome presenting with sepsis in the setting of otitis media and incidentally found to have a rare suprasellar spindle cell lipoma demonstrating loss of RB1 by immunohistochemistry, suggestive of a neoplastic etiology.

  PublisherDOI

• UNMASKING DOUBLE AORTIC ARCH AS AN UNCOMMON AND OVERLOOKED CAUSE OF AIRWAY OBSTRUCTION

  CHEST Journal · 2025-10-01

  articleSenior author
  PublisherDOI

• A Systematic Review of Adverse Events in Patients Undergoing Endobronchial Valve Therapy for Chronic Obstructive Pulmonary Disease

  2024-04-30

  reviewSenior author
  PublisherDOI

• The Complexity of Diagnosing Secondary Organizing Pneumonia

  2024-04-30 · 1 citations

  articleSenior author
  PublisherDOI

• Diabetes: A Potential Modifiable Risk Factor for Patients With Pulmonary Hypertension and Sarcoidosis

  2024-04-30

  articleSenior author
  PublisherDOI

• Comparative Analysis of Online English and Spanish Content on Post ICU Syndrome

  2024-04-30

  articleSenior author
  PublisherDOI

• Safe and effective use of cabozantinib and nivolumab in stabilizing disease progression of tissue sarcoma after multiple lines of standard therapy

  Journal of Case Reports and Images in Oncology · 2023-07-11

  articleOpen access

  Introduction: Soft-tissue sarcomas (STS) are a rare and varied group of tumors with limited treatment options. In recent years, immune checkpoint inhibitors have demonstrated efficacy in an increasing number of solid tumors. Nivolumab, a PD1-inhibitor, demonstrates improved overall survival (OS) and progression-free survival (PFS) in renal cell carcinoma, melanoma, and gastrointestinal stromal tumor (GIST). The tyrosine kinase inhibitor (TKI), cabozantinib, demonstrates an antitumor effect in osteosarcoma and Ewing sarcoma. Case Series: Here we describe two patients with recurrent and refractory STS. Both patients failed multiple lines of conventional therapy including neoadjuvant radiation, surgical resection, and palliative chemotherapy before achieving partial response with combination cabozantinib and nivolumab. Conclusion: These cases demonstrate the safety and efficacy of using combination nivolumab and cabozantinib in treatment of STS warranting further investigation of immunotherapy treatment.

  PublisherOA PDFDOI

• STUDYING THE DISTRIBUTION OF COAGULABLE EVENTS IN PATIENTS WITH OSA: A NATIONWIDE PERSPECTIVE

  CHEST Journal · 2021-10-01

  articleOpen accessSenior author
  PublisherOA PDFDOI

• STUDYING THE LINK BETWEEN IDIOPATHIC PULMONARY FIBROSIS AND GI REFLUX DISEASE: A NATIONWIDE PERSPECTIVE

  CHEST Journal · 2021-10-01

  articleOpen accessSenior author
  PublisherOA PDFDOI

• RITUXIMAB THERAPY FOR A CASE OF STEROID RESISTANT CRYPTOGENIC ORGANIZING PNEUMONIA

  CHEST Journal · 2021-10-01

  articleOpen accessSenior author
  PublisherOA PDFDOI

Frequent coauthors

• Daniel Ray

  Lehigh Valley Hospital-Pocono

  201 shared

• Paul Richman

  199 shared

• Paul A. Selecky

  Hoag Memorial Hospital Presbyterian

  199 shared

• Howard L. Saft

  University of Colorado Denver

  199 shared

• Dee W. Ford

  Medical University of South Carolina

  199 shared

• Richard A. Mularski

  Kaiser Permanente Center for Health Research

  198 shared

• Steven M. Asch

  196 shared

• Paul A. Kvale

  196 shared

Education

• M.D.

  Suny Stony Brook School of Medicine

  1988

• B.A.

  Vassar College

  1983

Awards & honors

• Recognition from NJMS and the New Jersey Health Foundation